Eupraxia Pharmaceuticals Inc（EPRX）資訊與事件EPRXEupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Announces New Analysis Results from RESOLVE Study

Eupraxia Pharmaceuticals announced results from a new analysis of the RESOLVE study examining the effect of EP-104GI on symptom severity, including for the first time an analysis of the effect of EP-104GI on odynophagia. This is important because odynophagia scoring is a component of Dysphagia Symptom Questionnaire, a commonly used patient reported outcome used in pivotal clinical trials in EoE patients. Patients in the RESOLVE trial were asked to grade the degree of odynophagia on an 11-point scale over the seven previous days. Measurements were recorded at baseline and at weeks 2, 4, 8, 12, 24, 36 and 52 following dosing with EP-104GI. Symptom severity was graded as most severe, severe, moderate, mild or none. An analysis of the distribution of severity of symptom score was performed for the patients that received 20 injections of EP-104GI. The results are presented in the figure below. At baseline 62% of the EoE patients reported either moderate or severe odynophagia. At 2, 4, 8 and 12 weeks post treatment, 31% of patients reported moderate or severe odynophagia. At 24, 36 and 52 weeks, 25% of patients reported moderate or severe odynophagia. At baseline, 15% of patients recorded no odynophagia, at 52 weeks, 50% of patients recorded no odynophagia. Patients in the RESOLVE trial were asked to grade the degree of dysphagia on an 11-point scale over the seven previous days. Measurements were recorded at baseline and at weeks 2, 4, 8, 12, 24, 36 and 52 following dosing with EP-104GI. Symptom severity was graded as most severe, severe, moderate, mild or none. An analysis of the distribution of severity of symptom score was performed for the patients that received 20 injections of EP-104GI.

Eupraxia CEO Highlights Key Milestones for EP-104GI

"Eupraxia is well funded with the experienced talent to execute on key upcoming milestones, including the Phase 2b Eosinophilic Esophagitis (EoE) trial with interim data expected to be released in Q4 highlighting key clinical and histologic endpoints, the subsequent Phase 3 trial initiation and the expansion of EP-104GI target indications to a broader GI portfolio in 2027. With the new appointments made this quarter to our executive team and Board, we are poised to progress EP-104GI into late-stage development and eventual commercialization" said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. "This year at DDW, it was clear that there is still a growing unmet need for patients living with EoE. With the additional data highlighting clinical improvement, fibrotic reversal and endoscopic resolution we believe that EP-104GI has the potential to be an impactful and durable treatment option."

Eupraxia Pharmaceuticals Files $300M Mixed Securities Shelf

Eupraxia Pharmaceuticals files $300M mixed securities shelf